

## BAB V

### KESIMPULAN DAN SARAN

#### A. Kesimpulan

Kesimpulan dari penelitian analisis pengaruh hubungan rasionalitas penggunaan antibiotik pada pasien *drugs tesistant tuberculosis* terhadap *outcome* klinik pasien di poli paru RSUP Dr. Sardjito adalah sebagai berikut:

1. Gambaran rasionalitas penggunaan antibiotik pada pasien rawat jalan *drug resistant tuberculosis* adalah sebesar 83,8% rasional dan 16,2% tidak rasional.
2. Hasil *outcome* klinik pasien *drug resistant tuberculosis* sebesar 87,1% membaik dan 12,9% belum membaik.
3. Terdapat hubungan rasionalitas penggunaan antibiotik terhadap *outcome klinik* ( $P < 0,05$ ).

#### B. Saran

1. Perlu penelitian lebih lanjut mengenai pengaruh penyakit penyerta pada pasien *drug resistant tuberculosis*.
2. Perlu adanya penelitian lebih lanjut mengenai hubungan rasionalitas per kategori dengan *outcome klinik* pasien *drug tesistant tuberculosis*.

## DAFTAR PUSTAKA

- Aznar, M.L., Marras, T.K., Elshal, A.S., Mehrabi, M., Brode, S.K., 2019, Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto Canada, *BMC Pharmacology and Toxicology* 20(37).
- Bakhla, A.K., Gore, P.S., Srivastava, S.L., 2013, Cycloserine induced mania, *Industrial Psychiatry Journal* 22(1) 68-70.
- Das, D., Singh, H., Cycloserine induced depression in a case of multidrug resistant tuberculosis, *World Journal of Pharmacy and Pharmaceutical Sciences* 6(10) 1069-1073.
- Depkes RI, 2007, *Pedoman Nasional Penanggulangan Tuberkulosis*, edisi 2 cetakan pertama, Jakarta.
- Duan, *et al.*, 2019, Clofazimin Improves Clinical Outcomes in Multidrug-resistant Tuberculosis: A Randomized Controlled Trial, *Clinical Microbiology and Infection* 25; 190-196.
- Duarte, R., Zao, I., Ribeiro, A.I., Marcoa, R., 2018, Tuberculosis and gender – Factors influencing the risk of tuberculosis among men and women by age group, *Pulmonology Journal*, 24(3) 199-202.
- Feng, J.Y., *et al.*, Gender differences in treatment outcomes of tuberculosis patients in Taiwan: a prospective observational study, *Cinical Microbiology and Infection Journal* 18(9) 331-337.
- Garcia, IS., Noguerado, A., 2012, Drug treatment of multidrug-resistant osteoarticular tuberculosis: a systematic literature review, *International Journal of Infectious Diseases* 16 e774-e778.
- Gler, M.T., Guilatco, R., Caoili, J.C., Ershova, J., Cegielski, P., Johnson, J.L., 2013, Weight Gain and Response to Treatment for Multidrug-Resistant Tuberculosis, *Am J Trop Med Hyg.* 89(5) 943–949.
- Gyssenss, I. C., 2005, *Audit for Monitoring the Quality of Antimicrobial Prescription*, 197-226, Kluwer Academic Publishers, New York.
- Huang, F., Zhang, H., Lv, Q., Sato, K. D., Qu, Y., Huan, S., Cheng, J., Zhao, F., Wang, L. (2016). Use of anti-tuberculosis drugs among newly diagnosed pulmonary tuberculosis inpatients in China: a retrospective study. *Infectious Diseases of Poverty*, 5(1).
- Depkes Queensland, 2015, *Guideline Treatment of Tuberculosis in Renal Disease*, Edisi 3, Direktorat Jenderal Pencegahan Penyakit, Queensland.
- Jepsen, P., 2014, Comorbidity in cirrhosis, *World J Gastroenterol* 20(23).

- Katiyar, S., Bihari, S., Prakash, S., Mamtani, M., Kulkarni, H., 2007, High-Dose Isoniazid Adjuvant Therapy for Multidrug Resistant Tuberculosis, *International Journal of Tuberculosis Lung Disease* 12(2) 139-45.
- Kemenkes RI, 2011, *Modul Penggunaan Obat Rasional*, Direktorat Jenderal Bina Kefarmasian dan Alat Kesehatan, Jakarta.
- Kemenkes RI, 2013, *Petunjuk Teknis Manajemen Terpadu Pengendalian Tuberkulosis Resistan Obat*. Direktorat Jenderal Pengendalian dan Pencegahan Penyakit Kemenkes RI, Jakarta.
- Kemenkes RI, 2014, *Pedoman Nasional Pengendalian Tuberkulosis*, Direktorat Jenderal Pengendalian dan Pencegahan Penyakit Kemenkes RI, Jakarta.
- Kemenkes RI, 2015, *Petunjuk Teknis Pelayanan Tuberkulosis Bagi Peserta Jaminan Kesehatan Nasional (JKN)*. Direktorat Jenderal Pengendalian dan Pencegahan Penyakit Kemenkes RI, Jakarta.
- Kemenkes RI, 2018, *Pusdatin Tuberkulosis*, Jakarta.
- Komurcuoglu, B., Senol, G., Balci, G., Yalniz, G., Ozden, E., 2013, Drug resistance in pulmonary tuberculosis in new and previously treated cases: Experience from Turkey, *Journal of Infection and Public Health* 6(4) 276-282.
- Nahid, *et al.*, 2019, Treatment of Drug-Resistant Tuberculosis An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline, *Am J Respir Crit Care Med* Vol 200, Iss 10, pp e93–e142.
- Nasiri, *et al.*, 2016, Primary Ethambutol Resistance among Iranian Pulmonary Tuberculosis Patients: A Systematic Review, *Therapeutics Advances in Infectious Disease* Vol.3(5) 133-138.
- Permenkes RI, 2013, *Pedoman Manajemen Terpadu Pengendalian Tuberkulosis Resistan Obat*, Menkes RI, Jakarta.
- Permenkes RI, 2016, *Penanggulangan Tuberkulosis*, Menkes RI, Jakarta.
- PDPI, 2006, *Tuberkulosis: Pedoman Diagnosis dan Penatalaksanaan di Indonesia*, Perhimpunan Dokter Paru Indonesia, Indonesia.
- Phuong, N. T. M., Nhung, N. V., Hoa, N. B., Thuy, H. T., Takarinda, K. C., Tayler-Smith, K., & Harries, A. D. (2016). *Management and treatment outcomes of patients enrolled in MDR-TB treatment in Viet Nam. Public Health Action*, 6(1), 25–31. doi:10.5588/pha.15.0068
- PNPK, 2013, *Pedoman Nasional Pelayanan Kedokteran Tata Laksana Tuberkulosis*, Kemenkes RI, Jakarta.
- Prado, T. N., *et al.*, 2017, Clinical and epidemiological characteristics associated with unfavorable tuberculosis treatment outcomes in TB-HIV co-infected patients in Brazil: a hierarchical polytomous analysis, *The Brazilian Journal of Infectious Diseases* 21(2) 162-170.
- Prasad, R., Gupta, N., Banka, A., 2018, Multidrugresistant tuberculosis/rifampicin-resistant tuberculosis: Principles of management. *Lung India* vol 35:78-81.

- Ramalho, D. M. P., Miranda, P. F. C., Andrade, M. K., Brígido, T., Dalcolmo, M. P., Mesquita, E., Dias, C. F., Gambirasio, A. N., Uelers Braga, J., Detjen, A., Phillips, P. P. J., Langley, I., Fujiwara, P. I., Squire, S. B., Oliveira, M. M., Kritski, A. L., 2017, Outcomes from patients with presumed drug resistant tuberculosis in five reference centers in Brazil, *BMC Infectious Diseases*, 17(1).
- Rao, S., 2009, Tuberculosis and patient gender: An analysis and its implications in tuberculosis control, *Lung India Journal*, 26(2).
- Samuel, J.P., Sood, A., Campbell, J.R., Khan, F.A., Johnngston, J.C., 2018, Comorbidities and treatment outcomes in multidrug resistant tuberculosis: a systematic review and meta-analysis, *Science Reports Nature Research* 8(4980).
- Sisay, M., Mengitsu, G., Bereket, M., Molla, B., Amare, F., Gabriel, T., 2017, Evaluation of rational drug use based on World Health Organization core drug use indicators in selected public hospitals of eastern Ethiopia: a cross sectional study, *BMC Health Services Research* 17 (161).
- Sutoyo, D.K., 2014, *Pengobatan Multidrug Resistant Tuberculosis (MDR-TB) dengan Paduan Jangka Pendek*, Fakultas Kedokteran Universitas Indonesia, Jakarta.
- Suyanto, et al., 2018, *Analisis Data Penelitian: Petunjuk Praktis Bagi Mahasiswa Kesehatan Menggunakan SPSS*, Unissula Press, Semarang.
- Valderas, J.M., Starfield, B., Sibbald, B., Salisbury, C., Roland, M., 2009, Defining Comorbidity: Implications for Understanding Health and Health Services, *Annals of Family Medicine* 2(4).
- Van der Werf, M. J., Langendam, M. W., Huitric, E., Manissero, D., 2011, Multidrug resistance after inappropriate tuberculosis treatment: a meta-analysis, *European Respiratory Journal*, 39(6), 1511–1519.
- Vega., et al., 2018, The updated Charlson comorbidity index is a useful predictor of mortality in patients with *Staphylococcus aureus* bacteraemia, *Epidemiology and Infection* 146,2122–2130.
- WHO, 2014, *Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis*, Switzerland.
- WHO, 2019, *WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment*, Switzerland.
- Widiastuti, E.N., Subronto, Y. W., Promono, D., 2017, Determinan kejadian multi-drug resistant tuberculosis di rumah sakit Dr. Sardjito Yogyakarta, *BKM Journal of Community Medicine and Public Health* 33(7) 325-330.
- Workneh, M.H., Bjune, G.A., Yimer, S.A., Prevalence and associated factors of tuberculosis and diabetes mellitus comorbidity: A systematic review. *PLoS ONE* 12(4): e0175925.
- Xu Y., Wu J., Liao S., Sun Z., 2017, Treating tuberculosis with high doses of anti-TB drugs: mechanisms and outcomes, *Annals of Clinical Microbiology and Antimicrobials* 16(67).